Hosted on MSN17h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...
secondariesinvestor9d
Inflexion shops $2bn-plus European multi-asset continuation fund
Inflexion has assets under management of £11 billion ($13.8 billion; €13.2 billion) and has backed over 120 businesses, ...
Investing5d
Evercore sees a buying opportunity in Nvidia stock after DeepSeek sell-off
However, citing its channel checks with senior AI engineers at major hyperscalers, Evercore notes that while DeepSeek offers cost improvements, these are seen as “evolutionary rather than ...
Yahoo Finance24d
Evercore adds UPS stock to Tactical Outperform list on improving data
Evercore made slight adjustments to its estimates, reducing the Q4 2024 EPS forecast to $2.54 from $2.56 and the full-year 2025 estimate to $8.77 from $8.84, primarily due to softer international ...
Morningstar5d
David Kamo Joins Evercore as Senior Managing Director in Investment Banking
Evercore (NYSE: EVR) announced today that David Kamo has joined the firm as a senior managing director to support its growing financial sponsor M&A advisory business,based in New York. “We are ...